Table 2.
Examples of the impact of anti-CD47 treatments in different types of cancer.
| Cancer | Treatment | Target | Impact | References |
|---|---|---|---|---|
| Acute myeloid leukemia (AML) | B6H12 | CD47 | Increased phagocytotic activity of macrophages; reduced tumor cell engraftment | (38) |
| C47B157, C47B161, C47B222, B6H12.2 | CD47 | Reduced peripheral AML cell number | (88) | |
| IgG1 C47B222-CHO | CD47 | Reduced AML cell number in the spleen but not bone marrow | ||
| ZF1 | CD47 | Increased phagocytosis of leukemia stem cells | (59) | |
| Acute lymphoblastic leukemia (ALL) | CC2C6 | CD47 | Increased Jurkat cell death | (91) |
| Lymphoma | Rituximab and Hu5F9-G4 | CD47 | Increased cancer cell phagocytosis | (111) |
| Multiple myeloma (MM) | KPMM2 cells | CD47 | Increased cancer cell apoptosis; increased survival | (84) |
| Anti-TSP-1 antibody | TSP-1 | Reduced osteoclast formation | (12) | |
| B6H12 | CD47 | Increased phagocytosis of myeloma cells; reduced tumor growth; increased survival | (33) | |
| Liver cancer | Anti-CD47 antibody | CD47 | Increased phagocytotic activity of macrophages; reduced tumor growth | (65) |
| 4MU | CD47 | Reduced CD47 expression on hepatic cancer cells | (115) | |
| 4MU and AdIL-12 | CD47 | Increased cytotoxic T-cell-specific response | ||
| Colorectal cancer | Hu5F9-G4 | CD47 | Unaltered phagocytosis | (116) |
| KWAR23 and cetuximab | SIRPα | Increased macrophage-mediated phagocytosis of colorectal adenocarcinoma cells; reduced tumor growth | (19) | |
| Pancreatic cancer | Anti-hCD47 (B6H12) | CD47 | Unaltered tumor growth | (6) |
| Hu5F9-G4 | CD47 | Unaltered phagocytosis | (116) | |
| CD47-blocking antibody | CD47 | Reduced metastasis and increased survival | (6) | |
| CD47-CAR-T cells | CD47 | Reduced pancreatic cancer cell number; reduced tumor growth | (75) | |
| Nanoparticles loaded with gemcitabine and anti-CD47 antibody | CD47 | Increased pancreatic cancer cell apoptosis; reduced tumor growth | (117) | |
| Mithomycin A-loaded nanoparticles | CD47 | Reduced CD47 expression in tumor xenografts | (118) | |
| Leiomyosarcoma | A humanized anti-CD47 monoclonal antibody | CD47 | Increased phagocytosis and reduced tumor growth and metastasis | (30) |
| Breast cancer | Anthracyclines and Anti-CD47 antibody | CD47 | Reduced invasive breast tumor growth | (81) |
| Hu5F9-G4 | CD47 | Unaltered phagocytosis | (116) | |
| Small cell lung cancer (SCLC) | Hu5F9-G4 | CD47 | Unaltered phagocytosis | (116) |
| Hu5F9-G4 | CD47 | Reduced SCLC tumor growth | (41) | |
| Non-small cell lung cancer (NSCLC) | siRNA against CD47 | CD47 | Reduced CD47 expression | (101) |
| Urinary and bladder cancer | Anti-CD47 single-chain antibody nanoparticles | CD47 | Reduced tumor cell survival | (119) |
| Glioblastoma | shCD47 lentiviral vector | CD47 | Reduced CD47 expression | (53) |
| MIAP301 | CD47 | Reduced tumor growth and increased survival | ||
| Anti-CD47 monoclonal antibody | CD47 | Increased formation of autophagosomes | (120) | |
| Osteosarcoma | Hu5F9-G4 | CD47 | Unaltered phagocytosis | (116) |
| B6H12 | CD47 | Reduced metastasis | (104) |